IOrganBio Raises $2M Seed Round Led by First Star Ventures

Why It Matters

The infusion of capital accelerates iOrganBio’s ability to supply high‑quality human cells, a critical bottleneck in biotech R&D, and signals broader market confidence in cell‑based manufacturing as a growth engine for the drug‑development ecosystem.

Deal Summary

Chapel Hill-based human cell production startup iOrganBio raised $2M in a funding round led by First Star Ventures with participation from IndieBio, Cape Fear BioCapital, 2ndF, Terasaki Institute, and Alix Ventures. The company, founded in 2024, will use the capital to advance its cell production technologies.